Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), a company focused on the development of innovative treatments and therapies for cancer, in particular prostate cancer, recently released its financial results for the third quarter of 2016, reporting higher revenue and net income compared … Continue reading →

From somewhat humble beginnings back in 2005 as a parent structure for investment in and franchising of the extremely successful Hooters brand that has given rise to a bevy of successful imitators over the years, Chanticleer Holdings (NASDAQ: HOTR) has … Continue reading →

The era of the super bug is upon us, and Achaogen, Inc. (NASDAQ: AKAO) has joined the fray against them. For close to one hundred years, antibiotics have lowered the prevalence and severity of infectious diseases. Increasingly, though, it is … Continue reading →

Major Depressive Disorder (MDD) afflicts about 15 million Americans and is the leading cause of disability in the U.S. for those aged 15-44, according to the National Institute of Mental Health. Although experiencing the blues is part of the human … Continue reading →

A research report (http://dtn.fm/w6uT3) issued earlier this week by Aegis Capital Corp. shows that Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR) has lived up to its promise since 2004, when it received startup funding from the Army under the Small Business Technology … Continue reading →

The expansion in data usage and communications has continued to inflate beyond all predictions, with networks rapidly being pushed far beyond originally anticipated requirements. The unparalleled growth is expected to continue as developing technologies challenge existing capabilities, creating an unprecedented … Continue reading →

Aerie Pharmaceuticals. Inc. (NASDAQ: AERI) is a publicly traded clinical stage pharmaceutical company focusing on the discovery of innovative treatments for glaucoma and other eye ailments. Its leading product candidates, Rhopressa™ and Roclatan™, are believed to be effective for most … Continue reading →

Recently disclosed developments to the OTCQX Best Market platform are likely to reduce the pain of going and being public for both domestic and foreign companies. In a note to clients, Jason Paltrowitz, Executive VP of Corporate Services at OTC … Continue reading →

For a late-stage rare diseases focused boipharma innovator like Soligenix (OTCQB: SNGX), with up to $58 million of support for its Vaccines/BioDefense segment coming directly from NIAID contract funding (National Institute of Allergy and Infectious Diseases, a division of the … Continue reading →

Proposed amendments to the listing rules for the OTCQX Best Market are likely to benefit international companies. The rules, which will become effective from January 1, 2017, should make it easier for Canadian and other foreign companies to establish a … Continue reading →